Transgenic non-human animals capable of producing heterologous antibodies of various isotypes

• US 5,661,016 A
• Filed: 04/26/1993
• Issued: 08/26/1997
• Est. Priority Date: 08/29/1990
• Status: Expired due to Term

• Current Assignee: Genpharm Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Genpharm Incorporated (Bristol-Myers Squibb Company)
• Inventors: Kay, Robert M., Lonberg, Nils
• Primary Examiner(s): Ziska, Suzanne E.
• Application Number:
  US08/053,131
• Time in Patent Office: 1,583 Days
• Field of Search: 800/2, 435/172.2, 435/240.2, 530/388.1
• US Class Current: 435/452
• CPC Class Codes: A01K 2207/15 Humanized animals
• CPC Class Codes: A01K 2217/00 Genetically modified animals
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A01K 2217/072 maintaining or altering function, i.e. knock in
• CPC Class Codes: A01K 2227/105 Murine
• CPC Class Codes: A01K 2267/01 Animal expressing industrially exogenous proteins
• CPC Class Codes: A01K 2267/0381 Animal model for diseases of the hematopoietic system
• CPC Class Codes: A01K 67/0278 Knock-in vertebrates, e.g. humanised vertebrates
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002
• CPC Class Codes: C07K 16/2812 against CD4
• CPC Class Codes: C07K 16/3007 Carcino-embryonic Antigens
• CPC Class Codes: C07K 16/44 against material not provided for elsewhere , e.g. haptens, metals, DNA, RNA, amino acids
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/52 Constant or Fc region; Isotype
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C12N 15/8509 for producing genetically modified animals, e.g. transgenic
• CPC Class Codes: C12N 15/90 Stable introduction of foreign DNA into chromosome

Abstract

The invention relates to transgenic non-human animals capable of producing heterologous antibodies and transgenic non-human animals having inactivated endogenous immunoglobulin genes. In one aspect of the invention, endogenous immunoglobulin genes are suppressed by antisense polynucleotides and/or by antiserum directed against endogenous immunoglobulins. Heterologous antibodies are encoded by immunoglobulin genes not normally found in the genome of that species of non-human animal. In one aspect of the invention, one or more transgenes containing sequences of unrearranged heterologous human immunoglobulin heavy chains are introduced into a non-human animal thereby forming a transgenic animal capable of functionally rearranging transgenic immunoglobulin sequences and producing a repertoire of antibodies of various isotypes encoded by human immunoglobulin genes. Such heterologous human antibodies are produced in B-cells which are thereafter immortalized, e.g., by fusing with an immortalizing cell line such as a myeloma or by manipulating such B-cells by other techniques to perpetuate a cell line capable of producing a monoclonal heterologous antibody. The invention also relates to heavy and light chain immunoglobulin transgenes for making such transgenic non-human animals as well as methods and vectors for disrupting endogenous immunoglobulin loci in the transgenic animal.

Claims

1. A method for obtaining secondary repertoire, somatically mutated human immunoglobulin V gene segments encoding immunoglobin V regions reactive with a pre-selected antigen the method comprising:

antigenically stimulating a transgenic mouse with said pre-selected antigen said transgenic mouse having one or more transgenes containing DNA segments from unrearranged human immunoglobulin heavy and kappa light chain gene loci incorporated its germline DNA, said transgene or transgenes comprising a plurality of human V kappa gene segments, a plurality of human J kappa gene segments, a human kappa constant region gene segment, a plurality of human VH gene segments, a plurality of human DH gene segments, a plurality of human JH gene segments, a human mu switch segment, and a human mu constant region gene segment,

wherein a first subset of B lymphocytes of said transgenic mouse produce IgM immunoglobulin molecules encoded by functional rearrangement of said immunoglobulin heavy and kappa light chain gene loci, said functionally rearranged immunoglobulin genes having variable region sequences including FR1, CDR1, FR2, CDR2, and FR3 portions from said human V kappa or VH gene segments of said unrearranged gene loci,

and wherein a second subset of B lymphocytcs of said transgenic mouse produce non-IgM immunoglobulin molecules encoded by somatically mutated immunoglobulin heavy and kappa light chain gene loci, said somatically mutated immunoglobulin heavy and kappa light chin gene loci having variable region sequences including FR1, CDR1, FR2, CDR2, and FR3 portions of somatically mutated DNA sequences from said human V kappa or VH gene segments of said first subset; and

obtaining said somatically mutated human immunoglobulin V gene segments by (1) collecting somatically mutated V gene segments from said second subset of B lymphocytes or (2) immortalizing said second subset of B lymphocytes and then collecting somatically mutated V gene segments from said lymphocytes, wherein one or more of the somatically mutated V gene segments encode immunoglobulin V regions reactive with the preselected antigen.

2. The method of claim 1, wherein said J kappa and kappa constant region gene segments are contained within a BamHI DNA fragment of about 11 kb.

3. The method of claim 1, wherein said plurality of human DH gene segments includes DLR1, DXP1, DXP'"'"'1, and DA1 gene segments contained within an XhoI DNA fragment of about 5.2 kb.

4. The method of claim 1, wherein said JH gene, mu switch, and mu constant region gene segments are contained within a BamHI DNA fragment of about 16.3 kb.

5. The method of claim 1, wherein at least one of the transgenes includes the human VH251 gene segment.

6. The method of claim 1, wherein the VH gene segments include the sequence

5'"'"'-GAT CCT GGT TTA GTT AAA GAG GAT TTT ATT C&

C CCC TGT GTC-3'"'"' (Seq. ID NO;

27).

7. The method of claim 1, wherein the second subset of B lymphocytes express γ

isotype immunoglobulin chains.

8. The method of claim 7, wherein the γ

isotype is γ

₁ or γ

₃.

9. The method of claim 1, further comprising the step of expressing one or more collected V region gene segments in a host cell.

10. The method of claim 9, further comprising the step of purifying protein encoded by the expressed V region gene segment.

11. The method of claim 10, wherein the V region gene segment is linked to a human immunoglobulin constant region.

12. The method of claim 11, wherein at least one of the transgenes further comprises a human γ

gene segment.

13. The method of claim 12, wherein the constant region is a γ

isotype.

14. The method of claim 13, wherein the γ

isotype is a human γ

₁ isotype or a human γ

₃ isotype.

15. A method for obtaining secondary repertoire V regions reactive with a preselected antigen, said V regions encoded by somatically mutated human immunoglobulin V gene segments, the method comprising:

antigenically stimulating a transgenic mouse with said pre-selected antigen, said transgenic mouse having one or more transgenes containing DNA segments from unrearranged human immunoglobulin heavy and kappa light chain gene loci incorporated into its germline DNA, said transgene or transgenes comprising a plurality of human V kappa gene segments, a plurality of human J kappa gene segments, a human kappa constant region gene segment, a plurality of human VH gene segments, a plurality of human DH gene segments, a plurality of human JH gene segments, a human mu switch segment, and a human mu constant region gene segment,

wherein a subset of B lymphocytes of said transgenic mouse produce IgM immunoglobulin molecules encoded by functional rearrangement of said immunoglobulin heavy and kappa light chain gene loci, said functionally rearranged immunoglobulin genes having variable region sequences including FR1, CDR1, FR2, CDR2, and FR3 portions from said human V kappa or VH gene segments of said unrearranged gene loci,

and wherein a second subset of B lymphocytes of said transgenic mouse produce non-IgM immunoglobulin molecules encoded by somatically mutated immunoglobulin heavy and kappa light chain gene loci, said somatically mutated immunoglobulin heavy and kappa light chain gene loci having variable region sequences including FR1, CDR1, FR2, CDR2, and FR3 portions of somatically mutated DNA sequences from said human V kappa or VII gene segments; and

obtaining said secondary repertoire V regions reactive with said preselected antigen, by (1) collecting said somatically mutated immunoglobulin V gene segments from said second subset of B lymphocytes, and expressing collected V region gene segments in a host cell, or (2) immortalizing cells of said second subset of B lymphocytes and collecting said secondary repertoire V regions.

16. The method of claim 15 wherein at least one of the transgenes includes the human VH251 gene segment.

17. The method of claim 15, wherein the VH gene segments include the sequence 5'"'"'-GAT CCT GGT TTA GTT AAA GAG GAT TTT ATT CAC CCC TGT GTC-3'"'"' (Seq. ID NO:

27).

18. The method of claim 15, wherein the V region gene segment is linked to a human immunoglobulin constant region.

19. The method of claim 18, wherein at least one of the transgenes further comprises a human γ

gene segment.

20. The method of claim 19, wherein the constant region is a γ

isotype.

21. The method of claim 20, wherein the γ

isotype is a human γ

₁ isotype or a human γ

₃ isotype.